Teva Pharmaceutical Industries Limited (NYSE: TEVA) is one of 113 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Teva Pharmaceutical Industries Limited to similar businesses based on the strength of its risk, dividends, valuation, earnings, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Teva Pharmaceutical Industries Limited and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries Limited -25.18% 15.96% 5.31%
Teva Pharmaceutical Industries Limited Competitors -3,193.97% -54.68% -8.70%

Valuation and Earnings

This table compares Teva Pharmaceutical Industries Limited and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Teva Pharmaceutical Industries Limited $23.37 billion $7.42 billion -2.56
Teva Pharmaceutical Industries Limited Competitors $7.79 billion $2.46 billion 0.24

Teva Pharmaceutical Industries Limited has higher revenue and earnings than its peers. Teva Pharmaceutical Industries Limited is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Dividends

Teva Pharmaceutical Industries Limited pays an annual dividend of $0.94 per share and has a dividend yield of 6.0%. Teva Pharmaceutical Industries Limited pays out -15.4% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.3% and pay out 82.4% of their earnings in the form of a dividend. Teva Pharmaceutical Industries Limited is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.

Insider and Institutional Ownership

56.8% of Teva Pharmaceutical Industries Limited shares are owned by institutional investors. Comparatively, 43.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.1% of Teva Pharmaceutical Industries Limited shares are owned by company insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Teva Pharmaceutical Industries Limited has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries Limited’s peers have a beta of 0.87, meaning that their average share price is 13% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Teva Pharmaceutical Industries Limited and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries Limited 4 16 6 0 2.08
Teva Pharmaceutical Industries Limited Competitors 790 3408 5861 137 2.52

Teva Pharmaceutical Industries Limited presently has a consensus price target of $28.88, indicating a potential upside of 84.16%. As a group, “Pharmaceuticals” companies have a potential upside of 21.73%. Given Teva Pharmaceutical Industries Limited’s higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries Limited is more favorable than its peers.

Summary

Teva Pharmaceutical Industries Limited beats its peers on 10 of the 15 factors compared.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.